{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-004547","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2022-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.415342+00:00","generated_at":"2026-06-26T18:30:22.007354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Athira reports FY2021 net loss $54.9M; ACT-AD Phase 2 data on track for Q2 2022","bullets":["Net loss $54.9M ($1.49/share) vs $19.9M in 2020; R&D spend $42.8M, up from $13.3M.","Cash & investments $319.7M as of Dec 31, 2021; cash used in ops $43.1M in 2021.","Topline ACT-AD Phase 2 Alzheimer's data expected Q2 2022; LIFT-AD Phase 3 enrollment to complete Q3 2022.","First patient dosed in SHAPE Phase 2 in Parkinson's dementia / DLB; ATH-1020 Phase 1 initiated.","Appointed Grant Pickering and Dr. Michael Panzara to Board; expanded management team."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-004547","json":"https://secwatch.observer/filing/0000950170-22-004547.json","markdown":"https://secwatch.observer/filing/0000950170-22-004547.md","text":"https://secwatch.observer/filing/0000950170-22-004547.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017022004547/0000950170-22-004547-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017022004547/atha-20220324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T18:30:22.007354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}